Ligustilide

1 1

Selleck Chemicals

S9385-1MG

€144,00 EUR
€144,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

Ligustilide is an inhibitor linked to MAPK / ERK Signaling and related pathway-oriented research. It is especially relevant in cardiovascular models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling.

The pathway annotation connects Ligustilide to MAPK / ERK Signaling, supporting experiments that monitor mitogenic kinase cascades, proliferation control, and differentiation-linked signaling across biochemical, cellular, or phenotypic assay formats. This context is compatible with phosphorylation mapping, pathway-response, and growth assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In cardiovascular models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Pathway perturbation studies connected to MAPK / ERK Signaling
  • Concentration-response inhibition and target-dependence studies
  • Phenotypic profiling in cardiovascular models
  • Combination studies with orthogonal perturbagens

Overall, Ligustilide is well suited to pathway-oriented studies that need a defined compound input for MAPK / ERK Signaling readouts in cardiovascular models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Pathways:
MAPK / ERK Signaling
Research Area:
Cardiovascular
CAS No.:
4431-01-0
Molecular Weight:
190.24
Formula:
C₁₂H₁₄O₂
SMILES:
CCCC=C1C2=C(C=CCC2)C(=O)O1
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.